Tacrolimus-Induced Diabetic Ketoacidosis and Effect of Switching to Everolimus: A Case Report

Tugcu, M.; Kasapoglu, U.; Boynuegri, B.; Can, O.; Gokce, A.; Ruhi, CAGLAR; Titiz, M.

doi:10.1016/j.transproceed.2015.04.075

Tacrolimus-Induced Diabetic Ketoacidosis and Effect of Switching to Everolimus: A Case Report

Tugcu M., Kasapoglu U., Boynuegri B., Can O., Gokce A. M., Ruhi C., ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.47, sa.5, ss.1528-1530, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 47 Sayı: 5
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.transproceed.2015.04.075
Dergi Adı: TRANSPLANTATION PROCEEDINGS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1528-1530
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background. New-onset diabetes after transplantation (NODAT) is a common metabolic complication. Most conventional immunosuppressive medications, especially steroids and tacrolimus, are responsible for its development. NODAT may rarely be associated with severe, life-threating complications in kidney transplantation recipients.